Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 54 min ago
Peer-reviewedLicence not statedAnnals of Oncology

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial

  • Olivia Pagani1
  • Samuel M. Niman2
  • Monica Ruggeri3
  • Fedro Alessandro Peccatori4
  • Hatem A. Azim5
  • Marco Angelo Colleoni6
  • Cristina Saura7
  • Chikako Shimizu8
  • Anna Barbro Sætersdal9
  • Judith R. Kroep10
  • Ellen Warner11
  • Frédéric C. Amant12
27 more authors
  • Audrey Mailliez13
  • H.C.F. Moore14
  • Manuel Ruíz‐Borrego15
  • Janice Maria Walshe16
  • Virginia F. Borges17
  • Andrea Gombos18
  • Akemi Kataoka19
  • Christine Rousset‐Jablonski20
  • Simona Borštnar21
  • Junko Takei22
  • Jeong Eon Lee23
  • Christobel Mary Saunders24
  • Vesna Bjelic‐Radisic25
  • Snežana V. Šušnjar26
  • Fatima Cardoso27
  • Natalie J. Klar28
  • Teresa I. Ferreiro29
  • Karin Ribi30
  • Kathryn J. Ruddy31
  • Roswitha Kammler32
  • Sarra El-Abed33
  • Giuseppe Viale34
  • Martine J Piccart35
  • Larissa A. Korde36
  • Aron Goldhirsch37
  • Richard D. Gelber38
  • Ann H. Partridge39
39 affiliations
  1. 1Geneva University Hospitals, Geneva, Switzerland; University Hospitals, Lugano University, Lugano, Switzerland; Swiss Cancer Institute (Formerly SAKK), Bern, Switzerland
  2. 2International Breast Cancer Study Group Statistical Center, Boston, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA
  3. 3Program for Young Patients, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland
  4. 4Fertility and Procreation Unit, Gynecologic Oncology Program, IEO, European Institute of Oncology IRCCS, Milan, Italy
  5. 5Cairo Cure Oncology Center, Cairo, Egypt
  6. 6Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
  7. 7Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; SOLTI Breast Cancer Research Group, Barcelona, Spain
  8. 8Department of Breast and Medical Oncology, Japan Institute of Health Security - National Center for Global Health and Medicine, Tokyo, Japan
  9. 9Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway
  10. 10Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; Dutch Breast Cancer Group, BOOG, Utrecht, The Netherlands
  11. 11Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, Canada
  12. 12Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium; Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands
  13. 13Department of Medical Oncology, Centre Oscar Lambret, Lille, France
  14. 14Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA
  15. 15GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Virgen del Rocio Sevilla, Sevilla, Spain
  16. 16Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland
  17. 17Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, USA
  18. 18Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium
  19. 19Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
  20. 20Department of Surgery, Leon Berard Cancer Centre, Centre Léon Bérard, Lyon, France; INSERM U1290 RESHAPE, Lyon, France; Gynecology and Obstetrics Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France
  21. 21Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  22. 22St Luke's International Hospital, Breast Center, Tokyo, Japan
  23. 23Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea
  24. 24Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Royal Melbourne Hospital, Melbourne, VIC, Australia
  25. 25Breast Unit, Helios University Clinic Wuppertal, University Witten/Herdecke, Wuppertal, Germany; Austrian Breast and Colorectal Study Group (ABCSG), Vienna, Austria
  26. 26Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
  27. 27Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Advanced Breast Cancer (ABC) Global Alliance Lisbon, Lisbon, Portugal
  28. 28New York University Langone's Perlmutter Cancer Center, Breast Cancer Center, New York, USA
  29. 29Soul Reconnect, Barcelona, Spain
  30. 30Quality of Life Office, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland; Careum School of Health, Part of the Kalaidos University of Applied Sciences, Zurich, Switzerland
  31. 31Department of Oncology, Mayo Clinic, Rochester, USA
  32. 32Translational Research Coordination, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland
  33. 33Breast International Group (BIG), Brussels, Belgium
  34. 34International Breast Cancer Study Group Central Pathology Office, Bern, Switzerland; Department of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy
  35. 35Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast International Group (BIG), Brussels, Belgium
  36. 36Jazz Pharmaceuticals, Philadelphia, USA
  37. 37International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland; IEO, European Institute of Oncology, IRCCS, Milan, Italy
  38. 38International Breast Cancer Study Group Statistical Center, Boston, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA; Frontier Science and Technology Research Foundation, Boston, USA; Harvard TH Chan School of Public Health, Boston, USA; Harvard Medical School, Boston, USA
  39. 39Harvard Medical School, Boston, USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: [email protected]
Open at sourceDOICite

Related

  1. CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
    Anna-Christina Rambow, Tim Jannik Schröder, Gudrun Wagenpfeil +6
    Breast care (Basel, Switzerland)Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report.
    Mingzhi Cha, Hao Yi, HuiMing Li +1
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  3. Delusion of Pregnancy: An Updated Systematic Review.
    Matteo Angelo Fabris, Dawid Konrad Ścigała
    Journal of clinical medicinePeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  4. Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer
    Jorge R Ledesma, Joshua Nugent, Richard Cheng +9
    JNCI Cancer SpectrumPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  5. Primary Endocrine Therapy vs Upfront Surgery for Older Women With Estrogen Receptor–Positive Breast Cancer
    Neil Carleton, Jian Zou, Yangyang Mu +6
    JAMA Network OpenPeer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{pagani2026updated,
  title = {{Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial}},
  author = {Olivia Pagani and Samuel M. Niman and Monica Ruggeri and Fedro Alessandro Peccatori and Hatem A. Azim and Marco Angelo Colleoni and Cristina Saura and Chikako Shimizu and Anna Barbro Sætersdal and Judith R. Kroep and Ellen Warner and Frédéric C. Amant and Audrey Mailliez and H.C.F. Moore and Manuel Ruíz‐Borrego and Janice Maria Walshe and Virginia F. Borges and Andrea Gombos and Akemi Kataoka and Christine Rousset‐Jablonski and Simona Borštnar and Junko Takei and Jeong Eon Lee and Christobel Mary Saunders and Vesna Bjelic‐Radisic and Snežana V. Šušnjar and Fatima Cardoso and Natalie J. Klar and Teresa I. Ferreiro and Karin Ribi and Kathryn J. Ruddy and Roswitha Kammler and Sarra El-Abed and Giuseppe Viale and Martine J Piccart and Larissa A. Korde and Aron Goldhirsch and Richard D. Gelber and Ann H. Partridge},
  journal = {Annals of Oncology},
  year = {2026},
  month = may,
  doi = {10.1016/j.annonc.2026.05.699},
  url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC13501236/},
}
RIS
TY  - JOUR
TI  - Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial
AU  - Olivia Pagani
AU  - Samuel M. Niman
AU  - Monica Ruggeri
AU  - Fedro Alessandro Peccatori
AU  - Hatem A. Azim
AU  - Marco Angelo Colleoni
AU  - Cristina Saura
AU  - Chikako Shimizu
AU  - Anna Barbro Sætersdal
AU  - Judith R. Kroep
AU  - Ellen Warner
AU  - Frédéric C. Amant
AU  - Audrey Mailliez
AU  - H.C.F. Moore
AU  - Manuel Ruíz‐Borrego
AU  - Janice Maria Walshe
AU  - Virginia F. Borges
AU  - Andrea Gombos
AU  - Akemi Kataoka
AU  - Christine Rousset‐Jablonski
AU  - Simona Borštnar
AU  - Junko Takei
AU  - Jeong Eon Lee
AU  - Christobel Mary Saunders
AU  - Vesna Bjelic‐Radisic
AU  - Snežana V. Šušnjar
AU  - Fatima Cardoso
AU  - Natalie J. Klar
AU  - Teresa I. Ferreiro
AU  - Karin Ribi
AU  - Kathryn J. Ruddy
AU  - Roswitha Kammler
AU  - Sarra El-Abed
AU  - Giuseppe Viale
AU  - Martine J Piccart
AU  - Larissa A. Korde
AU  - Aron Goldhirsch
AU  - Richard D. Gelber
AU  - Ann H. Partridge
PY  - 2026
DA  - 2026/05/29
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2026.05.699
UR  - https://pmc.ncbi.nlm.nih.gov/articles/PMC13501236/
SN  - 0923-7534
SN  - 1569-8041
ER  -